TQB2450 Combined With Anlotinib Hydrochloride in the Perioperative Treatment of Hepatocellular Carcinoma Hydrochloride Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With a High Risk of Recurrence or Metastasis

NCT04888546 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Patients With Resectable Hepatocellular Carcinoma Who Are at High Risk of Recurrence or Metastasi

Interventions

DRUG: Anlotinib hydrochloride capsules＋ TQB2450 injection

Sponsor

Chinese Academy of Medical Sciences